Brokerages Set Cresco Labs Inc. (OTCMKTS:CRLBF) Price Target at $2.50

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $2.50.

Several equities analysts recently issued reports on the company. Cormark cut Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Roth Capital upgraded shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Finally, Atb Cap Markets downgraded shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th.

Cresco Labs Trading Up 2.6 %

OTCMKTS:CRLBF opened at $1.00 on Friday. Cresco Labs has a 1 year low of $0.96 and a 1 year high of $2.65. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The stock has a fifty day moving average price of $1.35 and a two-hundred day moving average price of $1.56. The stock has a market capitalization of $488.14 million, a price-to-earnings ratio of -5.00 and a beta of 1.73.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.